Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2017 Apr 6

PMID 28378927

Citations 238

Authors

Y Zhou

M Ingelman-Sundberg

V M Lauschke

Affiliations

Soon will be listed here.

Abstract

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic activity toward a plethora of clinically important medications. Thus, single nucleotide variants and copy number variations in CYP genes are major determinants of drug pharmacokinetics and toxicity and constitute pharmacogenetic biomarkers for drug dosing, efficacy, and safety. Strikingly, the distribution of CYP alleles differs considerably between populations with important implications for personalized drug therapy and healthcare programs. To provide a global distribution map of CYP alleles with clinical importance, we integrated whole-genome and exome sequencing data from 56,945 unrelated individuals of five major human populations. By combining this dataset with population-specific linkage information, we derive the frequencies of 176 CYP haplotypes, providing an extensive resource for major genetic determinants of drug metabolism. Furthermore, we aggregated this dataset into spectra of predicted functional variability in the respective populations and discuss the implications for population-adjusted pharmacological treatment strategies.

Citing Articles

Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in children.

Wolthuis D, Freriksen J, Ter Avest M, Kartha R, de Wildt S, Wijnsma K Pediatr Nephrol. 2025; .

PMID: 39900743 DOI: 10.1007/s00467-025-06688-3.

Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.

Mangoura S, Abdel-Raheem M, Eltyb H, Molla M, Hussein A Cancer Chemother Pharmacol. 2024; 95(1):12.

PMID: 39714624 PMC: 11666798. DOI: 10.1007/s00280-024-04723-y.

Prevalence of single-nucleotide variants in twenty-five pharmacogenes from a Cuban sample cohort.

Reyes-Reyes E, Herrera-Isidron J, Cuetara-Lugo E, Shkedy Z, Valkenborg D, Perez-Novo C Front Pharmacol. 2024; 15:1467036.

PMID: 39403135 PMC: 11472837. DOI: 10.3389/fphar.2024.1467036.

Exploration of pharmacokinetic differences between East Asians and Caucasians: insights from pharmacokinetic studies in healthy subjects.

Kim Y, Bae S, Chung W, Kwon J, Song I, Lee S Transl Clin Pharmacol. 2024; 32(3):127-136.

PMID: 39386270 PMC: 11458340. DOI: 10.12793/tcp.2024.32.e15.

Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.

Litonius K, Kulla N, Falkenbach P, Kristiansson K, Tarkiainen E, Ukkola-Vuoti L Clin Pharmacol Ther. 2024; 117(1):278-288.

PMID: 39365028 PMC: 11652815. DOI: 10.1002/cpt.3458.

References

Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L . A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):103-13. DOI: 10.1016/j.clpt.2005.10.002. View

Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Yokota J . Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev. 2002; 11(9):890-4. View

Auton A, Brooks L, Durbin R, Garrison E, Kang H, Korbel J . A global reference for human genetic variation. Nature. 2015; 526(7571):68-74. PMC: 4750478. DOI: 10.1038/nature15393. View

Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M . Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996; 278(1):441-6. View

Kawanishi C, Lundgren S, Agren H, Bertilsson L . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2003; 59(11):803-7. DOI: 10.1007/s00228-003-0701-4. View

Krishnakumar D, Gurusamy U, Dhandapani K, Surendiran A, Baghel R, Kukreti R . Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol. 2011; 26(2):295-306. DOI: 10.1111/j.1472-8206.2010.00917.x. View

Ward B, Gorski J, Jones D, Hall S, Flockhart D, Desta Z . The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003; 306(1):287-300. DOI: 10.1124/jpet.103.049601. View

Griese E, Ofori-Adjei D, Mikus G, Eichelbaum M . Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics. 2000; 9(6):715-23. View

Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo M, Delgado A, de Andres F . Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. Pharmacogenomics J. 2015; 16(2):113-23. DOI: 10.1038/tpj.2015.70. View

10.

Sim S, Ingelman-Sundberg M . The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010; 4(4):278-81. PMC: 3525213. DOI: 10.1186/1479-7364-4-4-278. View

11.

Eichelbaum M, Ingelman-Sundberg M, Evans W . Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57:119-37. DOI: 10.1146/annurev.med.56.082103.104724. View

12.

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

13.

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P . Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351(27):2827-31. DOI: 10.1056/NEJMoa041888. View

14.

Burger D, van der Heiden I, Porte C, van der Ende M, Groeneveld P, Richter C . Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006; 61(2):148-54. PMC: 1885008. DOI: 10.1111/j.1365-2125.2005.02536.x. View

15.

Bains R, Kovacevic M, Plaster C, Tarekegn A, Bekele E, Bradman N . Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet. 2013; 14:34. PMC: 3655848. DOI: 10.1186/1471-2156-14-34. View

16.

Garcia-Donas J, Esteban E, Leandro-Garcia L, Castellano D, Del Alba A, Climent M . Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011; 12(12):1143-50. DOI: 10.1016/S1470-2045(11)70266-2. View

17.

Tyndale R, Sellers E . Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001; 29(4 Pt 2):548-52. View

18.

Evans W, Relling M . Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286(5439):487-91. DOI: 10.1126/science.286.5439.487. View

19.

Mwinyi J, Hofmann Y, Pedersen R, Nekvindova J, Cavaco I, Mkrtchian S . The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci. 2010; 86(19-20):699-706. DOI: 10.1016/j.lfs.2010.02.021. View

20.

Zanger U, Klein K, Saussele T, Blievernicht J, Hofmann M, Schwab M . Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007; 8(7):743-59. DOI: 10.2217/14622416.8.7.743. View